Designing multivalent proteins based on natural killer cell receptors and their ligands as immunotherapy for cancer

References

• Lanier LL. NK cell recognition. Annu Rev Immunol. 2005;23:225–274.
   PubMed Web of Science ®Google Scholar
• Lanier LL. Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol. 2008;9:495–502.
   PubMed Web of Science ®Google Scholar
• Kruse PH, Matta J, Ugolini S, et al. Natural cytotoxicity receptors and their ligands. Immunol Cell Biol. 2014;92:221–229.
   PubMed Web of Science ®Google Scholar
• Raulet DH, Gasser S, Gowen BG, et al. Regulation of ligands for the NKG2D activating receptor. Annu Rev Immunol. 2013;31:413–441.
   PubMed Web of Science ®Google Scholar
• Bellora F, Castriconi R, Dondero A, et al. Human NK cells and NK receptors. Immunol Lett. 2014;161:168–173.
   PubMed Web of Science ®Google Scholar
• Chames P, Van Regenmortel M, Weiss E, et al. Therapeutic antibodies: successes, limitations and hopes for the future. Br J Pharmacol. 2009;157:220–233.
   PubMed Web of Science ®Google Scholar
• Byrne H, Conroy PJ, Whisstock JC, et al. A tale of two specificities: bispecific antibodies for therapeutic and diagnostic applications. Trends Biotechnol. 2013;31:621–632.
   PubMed Web of Science ®Google Scholar
• Koristka S, Cartellieri M, Theil A, et al. Retargeting of human regulatory T cells by single-chain bispecific antibodies. J Immunol. 2012;188:1551–1558.
   PubMed Web of Science ®Google Scholar
• Weiner LM, Surana R, Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol. 2010;10:317–327.
   PubMed Web of Science ®Google Scholar
• Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer. 2012;12:278–287.
   PubMed Web of Science ®Google Scholar
• Lameris R, de Bruin RC, Schneiders FL, et al. Bispecific antibody platforms for cancer immunotherapy. Crit Rev Oncol Hematol. 2014;92:153–165.
   PubMed Web of Science ®Google Scholar
• Miller JS. Therapeutic applications: natural killer cells in the clinic. Hematology Am Soc Hematol Educ Program. 2013;(2013:247–253.
   PubMedGoogle Scholar
• Scott SD. Rituximab: a new therapeutic monoclonal antibody for non-Hodgkin’s lymphoma. Cancer Pract. 1998;6:195–197.
   PubMedGoogle Scholar
• Maloney DG, Grillo-Lopez AJ, White CA, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphoma. Blood. 1997;90:2188–2195.
   PubMed Web of Science ®Google Scholar
• Seidel UJ, Schlegel P, Lang P. Natural killer cell mediated antibody-dependent cellular cytotoxicity in tumor immunotherapy with therapeutic antibodies. Front Immunol. 2013;4:76.
   PubMed Web of Science ®Google Scholar
• Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood. 2002;99:754–758.
   PubMed Web of Science ®Google Scholar
• Alinari L, Lapalombella R, Andritsos L, et al. Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia. Oncogene. 2007;26:3644–3653.
   PubMed Web of Science ®Google Scholar
• Golay J, Introna M. Mechanism of action of therapeutic monoclonal antibodies: promises and pitfalls of in vitro and in vivo assays. Arch Biochem Biophys. 2012;526:146–153.
   PubMed Web of Science ®Google Scholar
• Karlhofer FM, Ribaudo RK, Yokoyama WM. MHC class I alloantigen specificity of Ly-49+ IL-2-activated natural killer cells. Nature. 1992;358:66–70.
   PubMed Web of Science ®Google Scholar
• Moretta A, Vitale M, Bottino C, et al. P58 molecules as putative receptors for major histocompatibility complex (MHC) class I molecules in human natural killer (NK) cells. Anti-p58 antibodies reconstitute lysis of MHC class I-protected cells in NK clones displaying different specificities. J Exp Med. 1993;178:597–604.
   PubMed Web of Science ®Google Scholar
• Koh CY, Ortaldo JR, Blazar BR, et al. NK-cell purging of leukemia: superior antitumor effects of NK cells H2 allogeneic to the tumor and augmentation with inhibitory receptor blockade. Blood. 2003;102:4067–4075.
   PubMed Web of Science ®Google Scholar
• Barber MA, Zhang T, Gagne BA, et al. Ly49G2 receptor blockade reduces tumor burden in a leukemia model but not in a solid tumor model. Cancer Immunol Immunother. 2008;57:655–662.
   PubMed Web of Science ®Google Scholar
• Tajima K, Matsumoto N, Ohmori K, et al. Augmentation of NK cell-mediated cytotoxicity to tumor cells by inhibitory NK cell receptor blockers. Int Immunol. 2004;16:385–393.
   PubMed Web of Science ®Google Scholar
• Karre K, Ljunggren HG, Piontek G, et al. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature. 1986;319:675–678.
   PubMed Web of Science ®Google Scholar
• Romagne F, Andre P, Spee P, et al. Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells. Blood. 2009;114:2667–2677.
   PubMed Web of Science ®Google Scholar
• Lin W, Voskens CJ, Zhang X, et al. Fc-dependent expression of CD137 on human NK cells: insights into “agonistic” effects of anti-CD137 monoclonal antibodies. Blood. 2008;112:699–707.
   PubMed Web of Science ®Google Scholar
• Kohrt HE, Houot R, Goldstein MJ, et al. CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. Blood. 2011;117:2423–2432.
   PubMed Web of Science ®Google Scholar
• Kohrt HE, Houot R, Weiskopf K, et al. Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer. J Clin Invest. 2012;122:1066–1075.
   PubMed Web of Science ®Google Scholar
• Wu L, Adams M, Carter T, et al. lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. Clin Cancer Res. 2008;14:4650–4657.
   PubMed Web of Science ®Google Scholar
• Farag SS, Caligiuri MA. Cytokine modulation of the innate immune system in the treatment of leukemia and lymphoma. Adv Pharmacol. 2004;51:295–318.
   PubMedGoogle Scholar
• Domogala A, Madrigal JA, Saudemont A. Natural killer cell immunotherapy: from bench to bedside. Front Immunol. 2015;6:264.
   PubMed Web of Science ®Google Scholar
• Becknell B, Caligiuri MA. Interleukin-2, interleukin-15, and their roles in human natural killer cells. Adv Immunol. 2005;86:209–239.
   PubMed Web of Science ®Google Scholar
• Romee R, Foley B, Lenvik T, et al. NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17). Blood. 2013;121:3599–3608.
   PubMed Web of Science ®Google Scholar
• Bauer S, Groh V, Wu J, et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science. 1999;285:727–729.
   PubMed Web of Science ®Google Scholar
• Cosman D, Mullberg J, Sutherland CL, et al. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity. 2001;14:123–133.
   PubMed Web of Science ®Google Scholar
• Cerwenka A, Bakker AB, McClanahan T, et al. Retinoic acid early inducible genes define a ligand family for the activating NKG2D receptor in mice. Immunity. 2000;12:721–727.
   PubMed Web of Science ®Google Scholar
• Carayannopoulos LN, Naidenko OV, Fremont DH, et al. Cutting edge: murine UL16-binding protein-like transcript 1: a newly described transcript encoding a high-affinity ligand for murine NKG2D. J Immunol. 2002;169:4079–4083.
   PubMed Web of Science ®Google Scholar
• Diefenbach A, Jamieson AM, Liu SD, et al. Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages. Nat Immunol. 2000;1:119–126.
   PubMed Web of Science ®Google Scholar
• Smyth MJ, Swann J, Cretney E, et al. NKG2D function protects the host from tumor initiation. J Exp Med. 2005;202:583–588.
   PubMed Web of Science ®Google Scholar
• Guerra N, Tan YX, Joncker NT, et al. NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity. 2008;28:571–580.
   PubMed Web of Science ®Google Scholar
• Sentman CL, Meehan KR. NKG2D CARs as cell therapy for cancer. Cancer J. 2014;20:156–159.
   PubMed Web of Science ®Google Scholar
• Spear P, Barber A, Rynda-Apple A, et al. NKG2D CAR T-cell therapy inhibits the growth of NKG2D ligand heterogeneous tumors. Immunol Cell Biol. 2013;91:435–440.
   PubMed Web of Science ®Google Scholar
• Zhang T, Barber A, Sentman CL. Chimeric NKG2D modified T cells inhibit systemic T-cell lymphoma growth in a manner involving multiple cytokines and cytotoxic pathways. Cancer Res. 2007;67:11029–11036.
   PubMed Web of Science ®Google Scholar
• Barber A, Meehan KR, Sentman CL. Treatment of multiple myeloma with adoptively transferred chimeric NKG2D receptor-expressing T cells. Gene Ther. 2011;18:509–516.
   PubMed Web of Science ®Google Scholar
• Ruocco MG, Pilones KA, Kawashima N, et al. Suppressing T cell motility induced by anti-CTLA-4 monotherapy improves antitumor effects. J Clin Invest. 2012;122:3718–3730.
   PubMed Web of Science ®Google Scholar
• Smyth MJ, Swann J, Kelly JM, et al. NKG2D recognition and perforin effector function mediate effective cytokine immunotherapy of cancer. J Exp Med. 2004;200:1325–1335.
   PubMed Web of Science ®Google Scholar
• Jinushi M, Hodi FS, Dranoff G. Therapy-induced antibodies to MHC class I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicity. Proc Natl Acad Sci U S A. 2006;103:9190–9195.
   PubMed Web of Science ®Google Scholar
• Raab S, Steinbacher J, Schmiedel BJ, et al. Fc-optimized NKG2D-Fc constructs induce NK cell antibody-dependent cellular cytotoxicity against breast cancer cells independently of HER2/neu expression status. J Immunol. 2014;193:4261–4272.
   PubMed Web of Science ®Google Scholar
• Steinbacher J, Baltz-Ghahremanpour K, Schmiedel BJ, et al. An Fc-optimized NKG2D-immunoglobulin G fusion protein for induction of natural killer cell reactivity against leukemia. Int J Cancer. 2015;136:1073–1084.
   PubMed Web of Science ®Google Scholar
• Kellner C, Hallack D, Glorius P, et al. Fusion proteins between ligands for NKG2D and CD20-directed single-chain variable fragments sensitize lymphoma cells for natural killer cell-mediated lysis and enhance antibody-dependent cellular cytotoxicity. Leukemia. 2012;26:830–834.
   PubMed Web of Science ®Google Scholar
• von Strandmann EP, Hansen HP, Reiners KS, et al. A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivo. Blood. 2006;107:1955–1962.
   PubMed Web of Science ®Google Scholar
• Rothe A, Jachimowicz RD, Borchmann S, et al. The bispecific immunoligand ULBP2-aCEA redirects natural killer cells to tumor cells and reveals potent anti-tumor activity against colon carcinoma. Int J Cancer. 2014;134:2829–2840.
   PubMed Web of Science ®Google Scholar
• Huehls AM, Coupet TA, Sentman CL. Bispecific T-cell engagers for cancer immunotherapy. Immunol Cell Biol. 2015;93:290–296.
   PubMed Web of Science ®Google Scholar
• Baeuerle PA, Reinhardt C. Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res. 2009;69:4941–4944.
   PubMed Web of Science ®Google Scholar
• Goebeler ME, Knop S, Viardot A, et al. Bispecific T-cell engager (BiTE) antibody construct blinatumomab for the treatment of patients with relapsed/refractory non-hodgkin lymphoma: final results from a Phase I study. J Clin Oncol. 2016;34:1104–1111.
   PubMed Web of Science ®Google Scholar
• Wu MR, Zhang T, Gacerez AT, et al. B7H6-specific bispecific T cell engagers lead to tumor elimination and host antitumor immunity. J Immunol. 2015;194:5305–5311.
   PubMed Web of Science ®Google Scholar
• Brandt CS, Baratin M, Yi EC, et al. The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans. J Exp Med. 2009;206:1495–1503.
   PubMed Web of Science ®Google Scholar
• Zou J, Chen D, Zong Y, et al. Immunotherapy based on bispecific T-cell engager with hIgG1 Fc sequence as a new therapeutic strategy in multiple myeloma. Cancer Sci. 2015;106:512–521.
   PubMed Web of Science ®Google Scholar
• Zhang T, Sentman CL. Cancer immunotherapy using a bispecific NK receptor fusion protein that engages both T cells and tumor cells. Cancer Res. 2011;71:2066–2076.
   PubMed Web of Science ®Google Scholar
• Wang T, Sun F, Xie W, et al. A bispecific protein rG7S-MICA recruits natural killer cells and enhances NKG2D-mediated immunosurveillance against hepatocellular carcinoma. Cancer Lett. 2016;372:166–178.
   PubMed Web of Science ®Google Scholar
• Gleason MK, Ross JA, Warlick ED, et al. CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets. Blood. 2014;123:3016–3026.
   PubMed Web of Science ®Google Scholar
• Gleason MK, Verneris MR, Todhunter DA, et al. Bispecific and trispecific killer cell engagers directly activate human NK cells through CD16 signaling and induce cytotoxicity and cytokine production. Mol Cancer Ther. 2012;11:2674–2684.
   PubMed Web of Science ®Google Scholar
• Vallera DA, Zhang B, Gleason MK, et al. Heterodimeric bispecific single-chain variable-fragment antibodies against EpCAM and CD16 induce effective antibody-dependent cellular cytotoxicity against human carcinoma cells. Cancer Biother Radiopharm. 2013;28:274–282.
   PubMed Web of Science ®Google Scholar
• Wiernik A, Foley B, Zhang B, et al. Targeting natural killer cells to acute myeloid leukemia in vitro with a CD16 x 33 bispecific killer cell engager and ADAM17 inhibition. Clin Cancer Res. 2013;19:3844–3855.
   PubMed Web of Science ®Google Scholar
• Reiners KS, Kessler J, Sauer M, et al. Rescue of impaired NK cell activity in hodgkin lymphoma with bispecific antibodies in vitro and in patients. Mol Ther. 2013;21:895–903.
   PubMed Web of Science ®Google Scholar
• Singer H, Kellner C, Lanig H, et al. Effective elimination of acute myeloid leukemic cells by recombinant bispecific antibody derivatives directed against CD33 and CD16. J Immunother. 2010;33:599–608.
   PubMed Web of Science ®Google Scholar
• Soverini S, De Benedittis C, Papayannidis C, et al. Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: the main changes are in the type of mutations, but not in the frequency of mutation involvement. Cancer. 2014;120:1002–1009.
   PubMed Web of Science ®Google Scholar
• Kennedy GA, Tey SK, Cobcroft R, et al. Incidence and nature of CD20-negative relapses following rituximab therapy in aggressive B-cell non-Hodgkin’s lymphoma: a retrospective review. Br J Haematol. 2002;119:412–416.
   PubMed Web of Science ®Google Scholar
• Evans AG, Rothberg PG, Burack WR, et al. Evolution to plasmablastic lymphoma evades CD19-directed chimeric antigen receptor T cells. Br J Haematol. 2015 Jun 18. [Epub ahead of print]. doi:10.1111/bjh.13562.
   Web of Science ®Google Scholar
• Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol. 2013;14:1014–1022.
   PubMed Web of Science ®Google Scholar
• Muenst S, Laubli H, Soysal SD, et al. The immune system and cancer evasion strategies: therapeutic concepts. J Intern Med. J Intern Med. 2016 Jan 8. [Epub ahead of print]. doi:10.1111/joim.12470.
   Google Scholar
• Monjazeb AM, Zamora AE, Grossenbacher SK, et al. Immunoediting and antigen loss: overcoming the achilles heel of immunotherapy with antigen non-specific therapies. Front Oncol. 2013;3:197.
   PubMedGoogle Scholar
• Spranger S, Koblish HK, Horton B, et al. Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment. J Immunother Cancer. 2014;2:3.
   PubMedGoogle Scholar
• Bryceson YT, March ME, Ljunggren HG, et al. Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion. Blood. 2006;107:159–166.
   PubMed Web of Science ®Google Scholar
• Vales-Gomez M, Chisholm SE, Cassady-Cain RL, et al. Selective induction of expression of a ligand for the NKG2D receptor by proteasome inhibitors. Cancer Res. 2008;68:1546–1554.
   PubMed Web of Science ®Google Scholar
• Soriani A, Zingoni A, Cerboni C, et al. ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype. Blood. 2009;113:3503–3511.
   PubMed Web of Science ®Google Scholar
• Berghuis D, Schilham MW, Vos HI, et al. Histone deacetylase inhibitors enhance expression of NKG2D ligands in Ewing sarcoma and sensitize for natural killer cell-mediated cytolysis. Clin Sarcoma Res. 2012;2:8.
   PubMedGoogle Scholar
• Gasser S, Orsulic S, Brown EJ, et al. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature. 2005;436:1186–1190.
   PubMed Web of Science ®Google Scholar
• Baginska J, Viry E, Paggetti J, et al. The critical role of the tumor microenvironment in shaping natural killer cell-mediated anti-tumor immunity. Front Immunol. 2013;4:490.
   PubMed Web of Science ®Google Scholar
• Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol. 2007;25:267–296.
   PubMed Web of Science ®Google Scholar
• Carter P. Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer. 2001;1:118–129.
   PubMed Web of Science ®Google Scholar
• Weidle UH, Kontermann RE, Brinkmann U. Tumor-antigen-binding bispecific antibodies for cancer treatment. Semin Oncol. 2014;41:653–660.
   PubMed Web of Science ®Google Scholar